XML 49 R33.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Goodwill and Other Intangible Assets (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
Changes in carrying amount of goodwill | The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:
(In millions) | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Balance at December 31, 2019: |  |  |  |  |  |  |  |  |
Goodwill | $ | 8,258.0 |  |  | $ | 67.8 |  |  | $ | 584.8 |  |  | $ | 1,065.0 |  |  | $ | 9,975.6 |
Accumulated impairment losses | (385.0) |  |  | — |  |  | — |  |  | — |  |  | (385.0) |
| 7,873.0 |  |  | 67.8 |  |  | 584.8 |  |  | 1,065.0 |  |  | 9,590.6 |
Acquisitions | 704.3 |  |  | 652.8 |  |  | 217.4 |  |  | 533.0 |  |  | 2,107.5 |
Foreign currency translation | 607.2 |  |  | 17.7 |  |  | 61.8 |  |  | (37.8) |  |  | 648.9 |
| 9,184.5 |  |  | 738.3 |  |  | 864.0 |  |  | 1,560.2 |  |  | 12,347.0 |
Balance at December 31, 2020: |  |  |  |  |  |  |  |  |
Goodwill | 9,569.5 |  |  | 738.3 |  |  | 864.0 |  |  | 1,560.2 |  |  | 12,732.0 |
Accumulated impairment losses | (385.0) |  |  | — |  |  | — |  |  | — |  |  | (385.0) |
| 9,184.5 |  |  | 738.3 |  |  | 864.0 |  |  | 1,560.2 |  |  | 12,347.0 |
Measurement period and other adjustments | 67.7 |  |  | 220.4 |  |  | (30.9) |  |  | 38.4 |  |  | 295.6 |
Foreign currency translation | (528.8) |  |  | 10.8 |  |  | (56.8) |  |  | 45.9 |  |  | (528.9) |
| 8,723.4 |  |  | 969.5 |  |  | 776.3 |  |  | 1,644.5 |  |  | 12,113.7 |
Balance at December 31, 2021 |  |  |  |  |  |  |  |  |
Goodwill | 9,108.4 |  |  | 969.5 |  |  | 776.3 |  |  | 1,644.5 |  |  | 12,498.7 |
Accumulated impairment losses | (385.0) |  |  | — |  |  | — |  |  | — |  |  | (385.0) |
| $ | 8,723.4 |  |  | $ | 969.5 |  |  | $ | 776.3 |  |  | $ | 1,644.5 |  |  | $ | 12,113.7 |
Components of intangible assets | Intangible assets consist of the following components at December 31, 2021 and 2020:
(In millions) | Weighted Average Life (Years) |  | Cost |  | Accumulated Amortization |  | Net Book Value
December 31, 2021 |  |  |  |  |  |  |
Product rights, licenses and other (1) | 15 |  | $ | 39,006.2 |  |  | $ | 12,918.5 |  |  | $ | 26,087.7 |
In-process research and development |  |  | 46.5 |  |  | — |  |  | 46.5 |
|  |  | $ | 39,052.7 |  |  | $ | 12,918.5 |  |  | $ | 26,134.2 |
December 31, 2020 |  |  |  |  |  |  |
Product rights, licenses and other (1) | 15 |  | $ | 40,404.1 |  |  | $ | 10,801.6 |  |  | $ | 29,602.5 |
In-process research and development |  |  | 80.7 |  |  | — |  |  | 80.7 |
|  |  | $ | 40,484.8 |  |  | $ | 10,801.6 |  |  | $ | 29,683.2 |
____________ (1)Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.
Product rights and licenses by therapeutic category | Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by product category, is as follows:
(In millions) | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | December 31, 2021
Brands | $ | 10,066.6 |  |  | $ | 6,102.9 |  |  | $ | 1,174.8 |  |  | $ | 3,801.7 |  |  | $ | 21,146.0 |
Complex Gx and Biosimilars | 226.8 |  |  | — |  |  | 1.5 |  |  | — |  |  | 228.3 |
Generics | 4,020.2 |  |  | 12.1 |  |  | 319.5 |  |  | 358.4 |  |  | 4,710.2 |
Total Product Rights and Licenses | $ | 14,313.6 |  |  | $ | 6,115.0 |  |  | $ | 1,495.8 |  |  | $ | 4,160.1 |  |  | $ | 26,084.5 |
(In millions) | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | December 31, 2020
Brands | $ | 10,988.1 |  |  | $ | 4,372.3 |  |  | $ | 2,377.0 |  |  | $ | 4,478.7 |  |  | $ | 22,216.1 |
Complex Gx and Biosimilars | 272.5 |  |  | — |  |  | 2.3 |  |  | — |  |  | 274.8 |
Generics | 6,253.9 |  |  | 12.7 |  |  | 423.9 |  |  | 417.3 |  |  | 7,107.8 |
Total Product Rights and Licenses | $ | 17,514.5 |  |  | $ | 4,385.0 |  |  | $ | 2,803.2 |  |  | $ | 4,896.0 |  |  | $ | 29,598.7 |
Finite-lived Intangible Assets Amortization Expense [Table Text Block] | Amortization expense and intangible asset impairment charges, which are included as a component of amortization expense, which is classified primarily within cost of sales in the consolidated statements of operations, for the years ended December 31, 2021, 2020 and 2019 was as follows:
| Year ended December 31,
(In millions) | 2021 |  | 2020 |  | 2019
Intangible asset amortization expense | $ | 2,702.2 |  |  | $ | 1,605.8 |  |  | $ | 1,582.7 |
IPR&D intangible asset impairment charges | 19.4 |  |  | 37.4 |  |  | 138.3 |
Finite-lived intangible asset impairment charges | 83.4 |  |  | 45.0 |  |  | 42.3 |
Total intangible asset amortization expense (including impairment charges) | $ | 2,805.0 |  |  | $ | 1,688.2 |  |  | $ | 1,763.3 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | Intangible asset amortization expense for the years ending December 31, 2022 through 2026 is estimated to be as follows:
(In millions) |
2022 | $ | 2,577 |
2023 | 2,414 |
2024 | 2,320 |
2025 | 2,222 |
2026 | 2,164 |

X
- Definition Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267 + Details
Name: | us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product rights and licenses by therapeutic category + References No definition available. + Details
Name: | vtrs_ProductRightsAndLicensesByTherapeuticCategoryTableTextBlock
Namespace Prefix: | vtrs_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration